Forest Laboratories (FRX) 93.80 $FRX
Actavis Prices $3.7 Billion of Senior Unsecured Notes
PR Newswire - Tue Jun 10, 4:19PM CDT
Actavis plc (NYSE: ACT) today announced that its indirect subsidiary, Actavis Funding SCS, priced a private debt offering of $500 million of 1.300% senior unsecured notes due 2017, $500 million of 2.450% senior unsecured notes due 2019, $1.2 billion of 3.850% senior unsecured notes due 2024 and $1.5 billion of 4.850% senior unsecured notes due 2044, for a total offering of $3.7 billion in aggregate principal amount. The offering is expected to close on June 19, 2014, subject to market conditions and other factors.
Forest Laboratories Announces Intention to Continue Marketing Both NAMENDA(R) TABLETS and Once-Daily NAMENDA XR(R) Into the Fall of 2014
Business Wire - Tue Jun 10, 3:01PM CDT
-- Initiatives to Ensure Robust and Reliable Product Supply Progressing--
Actavis Announces Offering of Senior Unsecured Notes
PR Newswire - Tue Jun 10, 7:48AM CDT
Actavis plc (NYSE: ACT) today announced that its indirect subsidiary, Actavis Funding SCS, is privately offering three, five, ten and thirty year senior unsecured notes.
2014 Report on the International Pain Management Drugs Market - Forecasts to 2018
M2 - Tue Jun 10, 7:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7zh6gc/global_pain) has announced the addition of the "2014 Report on the International Pain Management Drugs Market - Forecasts to 2018" report to their offering. The analysts forecast the Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing global aging population. The Global Pain Management Drugs market has also been witnessing intense competition among vendors. However, the increase in generic competition could pose a challenge to the growth of this market. The report, 2014 Report on the International Pain Management Drugs Market - Forecasts to 2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Pain Management Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Category 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Actavis plc - Allergen Inc. - Astra Zenca plc - Baxter International Inc. - Bayer Healthcare AG - Boehringer Ingelheim GmbH - Boston Scientific Corp. - Bristol Myers Squibb Co. - Durect Corp. - Eli Lilly and Co. - Endo Health Solutions Inc. - F. Hoffmann La Roche Ltd. - Forest Laboratories Inc. - GlaxoSmithKline plc - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pain Therapeutics Inc. - Pfizer Inc. - Purdue Pharma L.P. - Sanofi S.A. - St. Jude Medical Inc. - UCB S.A. - Valeant Pharmaceuticals International Inc. - Zalicus Inc. For more information visit http://www.researchandmarkets.com/research/7z...lobal_pain
Forest Laboratories, Inc. Extends Expiration Time of Consent Solicitations to Eliminate Existing Registration Rights Obligations on Certain of its Senior Notes
Business Wire - Mon Jun 09, 7:01AM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced that it has extended the expiration date of its consent solicitations (the "Consent Solicitations"
to eliminate existing registration rights obligations with respect to its outstanding debt securities listed in the table below (the "FRX Notes" in exchange for the offer by Actavis plc (NYSE: ACT) to guarantee (the "ACT Guarantees" each of the FRX Notes. The Consent Solicitations were originally scheduled to expire at 5:00 p.m., New York City time, on June 6, 2014. The expiration date of the Consent Solicitations has been extended until 5:00 p.m., New York City time, on June 12, 2014.
Actavis Extends Expiration Time of Offer to Guarantee Certain Forest Laboratories Senior Notes in Connection with Forest Consent Solicitations
PR Newswire - Mon Jun 09, 7:00AM CDT
Actavis plc (NYSE: ACT) (the "Company" today announced that it has extended the expiration date of its offer to guarantee the outstanding debt securities listed in the table below (the "FRX Notes" of Forest Laboratories, Inc. (NYSE: FRX) in exchange for the elimination of the existing registration rights obligations with respect to each of those debt securities (the "Consent Solicitations" . The Consent Solicitations were originally scheduled to expire at 5:00 p.m., New York City time, on June 6, 2014. The expiration date of the Consent Solicitations has been extended until 5:00 p.m., New York City time, on June 12, 2014.
Clinical Study Results, Data Presentations, DMF Submissions, and Acquisition Agreements - Analyst Notes on Forest Laboratories, Incyte, Illumina, INSYS Therapeutics and AMRI
PR Newswire - Thu Jun 05, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Forest Laboratories Inc. (NYSE: FRX), Incyte Corporation (NASDAQ: INCY), Illumina Inc. (NASDAQ: ILMN), INSYS Therapeutics, Inc. (NASDAQ: INSY) and Albany Molecular Research Inc. (NASDAQ: AMRI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3391-100free.
Actavis Acquires Forest Labs For Brand-Name Drugs
at Investor's Business Daily - Mon Jun 02, 5:03PM CDT
Large-cap drugmaker Actavis is looking to acquisitions to expand beyond the generics domain and into the branded prescription-drug realm on the heels of strong profit gains. Actavis' (ACT) first-quarter adjusted earnings soared 75% from a year...
Active Stocks Technical Coverage -- Research on Forest Laboratories, NII Holdings, Endo Intl., and Aramark
PR Newswire - Mon Jun 02, 6:40AM CDT
The trading session on Friday, May 30, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,717.17, up 0.11% and the NASDAQ Composite closed at 4,242.62, down 0.13%. The S&P 500 finished the day 0.18% higher at 1,923.57. During the trading session, eight out of ten sectors finished on a positive note. Investor-Edge has initiated coverage on the following equities: Forest Laboratories Inc. (NYSE: FRX), NII Holdings Inc. (NASDAQ: NIHD), Endo International PLC (NASDAQ: ENDP) and Aramark (NYSE: ARMK). Free technical research on FRX, NIHD, ENDP and ARMK can be downloaded upon signing up at:
Anti-Depressants: The Secret to Preventing Alzheimer's?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat May 31, 3:52PM CDT
The Science Translational Medicine journal recently published research about the generic antidepressant citalopram, which was developed by Forest Laboratories under the brand name Celexa, as a potential way to help slow down the development of...
Forest Laboratories, Inc. Announces Publication in The Lancet of Pivotal Phase III Hypertension Trial of the Fixed-Dose Combination of Nebivolol/Valsartan
Business Wire - Fri May 30, 3:05PM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced the publication of data from its pivotal Phase III Study of an Investigational Fixed-Dose Combination (FDC) of nebivolol and valsartan in the May 30, 2014 issue of The Lancet. In the study, the combination of nebivolol and valsartan met its primary and key secondary endpoints, demonstrating statistically significant reductions from baseline in diastolic and systolic blood pressure vs. both nebivolol alone and valsartan alone at 8 weeks in patients with hypertension.
Actavis, Forest CEOs Team Up To Lead New Drug Giant
at Investor's Business Daily - Thu May 29, 3:47PM CDT
Brenton Saunders and Paul Bisaro have a lot of experience in making big pharma deals. Since he became CEO of generic drugmaker Watson Pharmaceuticals in 2007, Bisaro has built the company into a giant through its 2012 buyout of Actavis (ACT), whose...
Favorable Support, NDA Submission, Conference Schedule, Acquisition Update, and Executive Appointment - Analyst Notes on Allergan, Pfizer, Eli Lilly, Forest and Pharmacyclics
PR Newswire - Tue May 27, 6:20AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan, Inc. (NYSE: AGN), Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), Forest Laboratories, Inc. (NYSE: FRX) and Pharmacyclics, Inc. (NASDAQ: PCYC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2970-100free.
Research and Markets: Global Antibacterial Drugs Market Research Report 2014: Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides and Phenicols
Business Wire - Tue May 27, 3:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pdgs5q/antibacterial) has announced the addition of the "Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering.
Global Antibacterial Drugs Market Research Report 2014: Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides and Phenicols
M2 - Tue May 27, 2:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vjlj88/antibacterial) has announced the addition of the "Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Sanofi are the major players engaged in the development, production and marketing of various antibacterial drugs. The global antibacterial drugs market has been categorized into seven segments based on their class, namely, aminoglycosides, ?-lactams, tetracyclines, sulfonamides, quinolones/ fluoroquinolones, macrolides and phenicols. In 2012, ?-lactams class occupied the leading position with a share of 57.1% of the global antibacterial drugs market followed by the quinolones. However, these drug classes are expected to witness decline in their market share during the forecast period due to patent expiry of key branded formulations and growing number of drug resistant bacterial strains. Hence, on account of the above mentioned factors, the global antibacterial drugs market is expected to witness slow growth during the forecast period 2013 to 2019. However, growing demand for therapies against bacterial infections and rising elderly populations are some of the factors that are anticipated to maintain steady growth of the antibacterial drugs market. Additionally, expected launch of various antibacterial agents that are currently in developmental stages, such as tedizolid (Cubist Pharmaceuticals), Dalvance (Durata Therapeutics), surotomycin (Cubist Pharmaceuticals), MK-3415A (Merck) during the forecast period is also expected to restore growth of this market. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Antibacterial Drugs Market Revenue, by Class, 2011 - 2019 (USD Million) Chapter 5 Global Antibacterial Drugs Market Revenue, Pipeline Analysis (USD Million) Chapter 6 Global Antibacterial Drugs Market Revenue, by Geography, 2011 - 2019 (USD Million) Chapter 7 Competitive Landscape Chapter 8 Recommendations Chapter 9 Company Profiles - AstraZeneca plc - Bayer AG - Bristol-Myers Squibb Company - Eli Lilly and Company - Forest Laboratories, Inc. - GlaxoSmithKline plc - Johnson & Johnson - Merck & Co., Inc. - Novartis AG - Pfizer, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/vj...ibacterial
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of Furiex Pharmaceuticals, Inc. of Claims Against Board of Directors of Company in Connection With the Sale of the Company to Forest Laboratories, Inc. -- FURX
GlobeNewswire - Fri May 23, 1:01PM CDT
Levi & Korsinsky reminds investors of Furiex Pharmaceuticals, Inc. ("Furiex" or "the Company" (Nasdaq:FURX) of claims of breaches of fiduciary duty and other violations of state law against the board of directors of the Company in connection with the sale of the Company to Forest Laboratories, Inc. ("Forest" . A complaint was filed in Delaware state court.
Milestone Payments for Adamas - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 22, 4:10PM CDT
Adamas (ADMS) received a milestone payment of $25 million from Forest Labs (FRX) related to MDX-8704.
SHAREHOLDER ALERT: Brower Piven Announces Class Action Lawsuit in Connection with the Sale of Furiex Pharmaceuticals, Inc. to Forest Laboratories, Inc. and Royal Empress, Inc.
Business Wire - Thu May 22, 2:39PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the Delaware Chancery Court on behalf of all common stockholders of Furiex Pharmaceuticals, Inc. ("Furiex" or the "Company" (NasdaqGS: FURX) asserting claims that the members of the Company's board of directors have breached fiduciary duties they owe to Furiex shareholders.
Research and Markets: Global Neuropathic Pain Report 2014: Grnenthal's Cebranopadol - Forecast and Market Analysis to 2022
Business Wire - Thu May 22, 11:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q53s8z/cebranopadol) has announced the addition of the "Cebranopadol (Neuropathic Pain) - Forecast and Market Analysis to 2022" report to their offering.
Global Neuropathic Pain Report 2014: Grunenthal's Cebranopadol - Forecast and Market Analysis to 2022
M2 - Thu May 22, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8s2vl4/cebranopadol) has announced the addition of the "Cebranopadol (Neuropathic Pain) - Forecast and Market Analysis to 2022" report to their offering. Cebranopadol (GRT-6005) is a small-molecule opioid analgesic that is being developed by Gr?nenthal for the treatment of moderate to severe chronic pain conditions. In December 2010, Gr?nenthal entered into a licensing agreement with Forest Laboratories for the co-development and commercialization of cebranopadol and its follow-on compound, GRT-6006. The drug is currently in Phase IIb of clinical development for PDN, and is also in Phase III of development for cancer pain, as well as in Phase II for chronic nociceptive pain, moderate to severe pain due to osteoarthritis of the knee, and chronic low back pain. Scope - Overview of Neuropathic pain, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Cebranopadol including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Cebranopadol for the top six countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain and the UK. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview - Painful Diabetic Neuropathy - Postherpetic Neuralgia - Trigeminal Neuralgia - Etiology - Pathophysiology 4 Disease Management - Diagnosis - Treatment Overview and Guidelines 5 Competitive Assessment 6 Unmet Need and Opportunity - Physician Knowledge or Awareness - Diagnostic Challenges - Low Treatment Rate and Underdosing of Medications - Unsatisfactory Efficacy and Safety Profiles of Pharmacological Treatments - Elderly Patient Population - Drug Tolerability - Rational or Personalized Therapies 7 Pipeline Assessment - Promising Drugs in Clinical Development 8 Cebranopadol - Overview - Efficacy - Safety - Dosing and Formulation - Potential Clinical and Commercial Positioning - Pricing and Reimbursement - SWOT Analysis - Forecast 9 Appendix For more information visit http://www.researchandmarkets.com/research/8s...branopadol
Actavis Prices $3.7 Billion of Senior Unsecured Notes
PR Newswire - Tue Jun 10, 4:19PM CDT
Actavis plc (NYSE: ACT) today announced that its indirect subsidiary, Actavis Funding SCS, priced a private debt offering of $500 million of 1.300% senior unsecured notes due 2017, $500 million of 2.450% senior unsecured notes due 2019, $1.2 billion of 3.850% senior unsecured notes due 2024 and $1.5 billion of 4.850% senior unsecured notes due 2044, for a total offering of $3.7 billion in aggregate principal amount. The offering is expected to close on June 19, 2014, subject to market conditions and other factors.
Forest Laboratories Announces Intention to Continue Marketing Both NAMENDA(R) TABLETS and Once-Daily NAMENDA XR(R) Into the Fall of 2014
Business Wire - Tue Jun 10, 3:01PM CDT
-- Initiatives to Ensure Robust and Reliable Product Supply Progressing--
Actavis Announces Offering of Senior Unsecured Notes
PR Newswire - Tue Jun 10, 7:48AM CDT
Actavis plc (NYSE: ACT) today announced that its indirect subsidiary, Actavis Funding SCS, is privately offering three, five, ten and thirty year senior unsecured notes.
2014 Report on the International Pain Management Drugs Market - Forecasts to 2018
M2 - Tue Jun 10, 7:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7zh6gc/global_pain) has announced the addition of the "2014 Report on the International Pain Management Drugs Market - Forecasts to 2018" report to their offering. The analysts forecast the Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing global aging population. The Global Pain Management Drugs market has also been witnessing intense competition among vendors. However, the increase in generic competition could pose a challenge to the growth of this market. The report, 2014 Report on the International Pain Management Drugs Market - Forecasts to 2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Pain Management Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Category 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Actavis plc - Allergen Inc. - Astra Zenca plc - Baxter International Inc. - Bayer Healthcare AG - Boehringer Ingelheim GmbH - Boston Scientific Corp. - Bristol Myers Squibb Co. - Durect Corp. - Eli Lilly and Co. - Endo Health Solutions Inc. - F. Hoffmann La Roche Ltd. - Forest Laboratories Inc. - GlaxoSmithKline plc - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pain Therapeutics Inc. - Pfizer Inc. - Purdue Pharma L.P. - Sanofi S.A. - St. Jude Medical Inc. - UCB S.A. - Valeant Pharmaceuticals International Inc. - Zalicus Inc. For more information visit http://www.researchandmarkets.com/research/7z...lobal_pain
Forest Laboratories, Inc. Extends Expiration Time of Consent Solicitations to Eliminate Existing Registration Rights Obligations on Certain of its Senior Notes
Business Wire - Mon Jun 09, 7:01AM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced that it has extended the expiration date of its consent solicitations (the "Consent Solicitations"
to eliminate existing registration rights obligations with respect to its outstanding debt securities listed in the table below (the "FRX Notes" in exchange for the offer by Actavis plc (NYSE: ACT) to guarantee (the "ACT Guarantees" each of the FRX Notes. The Consent Solicitations were originally scheduled to expire at 5:00 p.m., New York City time, on June 6, 2014. The expiration date of the Consent Solicitations has been extended until 5:00 p.m., New York City time, on June 12, 2014. Actavis Extends Expiration Time of Offer to Guarantee Certain Forest Laboratories Senior Notes in Connection with Forest Consent Solicitations
PR Newswire - Mon Jun 09, 7:00AM CDT
Actavis plc (NYSE: ACT) (the "Company"
today announced that it has extended the expiration date of its offer to guarantee the outstanding debt securities listed in the table below (the "FRX Notes" of Forest Laboratories, Inc. (NYSE: FRX) in exchange for the elimination of the existing registration rights obligations with respect to each of those debt securities (the "Consent Solicitations" . The Consent Solicitations were originally scheduled to expire at 5:00 p.m., New York City time, on June 6, 2014. The expiration date of the Consent Solicitations has been extended until 5:00 p.m., New York City time, on June 12, 2014. Clinical Study Results, Data Presentations, DMF Submissions, and Acquisition Agreements - Analyst Notes on Forest Laboratories, Incyte, Illumina, INSYS Therapeutics and AMRI
PR Newswire - Thu Jun 05, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Forest Laboratories Inc. (NYSE: FRX), Incyte Corporation (NASDAQ: INCY), Illumina Inc. (NASDAQ: ILMN), INSYS Therapeutics, Inc. (NASDAQ: INSY) and Albany Molecular Research Inc. (NASDAQ: AMRI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3391-100free.
Actavis Acquires Forest Labs For Brand-Name Drugs
at Investor's Business Daily - Mon Jun 02, 5:03PM CDT
Large-cap drugmaker Actavis is looking to acquisitions to expand beyond the generics domain and into the branded prescription-drug realm on the heels of strong profit gains. Actavis' (ACT) first-quarter adjusted earnings soared 75% from a year...
Active Stocks Technical Coverage -- Research on Forest Laboratories, NII Holdings, Endo Intl., and Aramark
PR Newswire - Mon Jun 02, 6:40AM CDT
The trading session on Friday, May 30, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,717.17, up 0.11% and the NASDAQ Composite closed at 4,242.62, down 0.13%. The S&P 500 finished the day 0.18% higher at 1,923.57. During the trading session, eight out of ten sectors finished on a positive note. Investor-Edge has initiated coverage on the following equities: Forest Laboratories Inc. (NYSE: FRX), NII Holdings Inc. (NASDAQ: NIHD), Endo International PLC (NASDAQ: ENDP) and Aramark (NYSE: ARMK). Free technical research on FRX, NIHD, ENDP and ARMK can be downloaded upon signing up at:
Anti-Depressants: The Secret to Preventing Alzheimer's?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat May 31, 3:52PM CDT
The Science Translational Medicine journal recently published research about the generic antidepressant citalopram, which was developed by Forest Laboratories under the brand name Celexa, as a potential way to help slow down the development of...
Forest Laboratories, Inc. Announces Publication in The Lancet of Pivotal Phase III Hypertension Trial of the Fixed-Dose Combination of Nebivolol/Valsartan
Business Wire - Fri May 30, 3:05PM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced the publication of data from its pivotal Phase III Study of an Investigational Fixed-Dose Combination (FDC) of nebivolol and valsartan in the May 30, 2014 issue of The Lancet. In the study, the combination of nebivolol and valsartan met its primary and key secondary endpoints, demonstrating statistically significant reductions from baseline in diastolic and systolic blood pressure vs. both nebivolol alone and valsartan alone at 8 weeks in patients with hypertension.
Actavis, Forest CEOs Team Up To Lead New Drug Giant
at Investor's Business Daily - Thu May 29, 3:47PM CDT
Brenton Saunders and Paul Bisaro have a lot of experience in making big pharma deals. Since he became CEO of generic drugmaker Watson Pharmaceuticals in 2007, Bisaro has built the company into a giant through its 2012 buyout of Actavis (ACT), whose...
Favorable Support, NDA Submission, Conference Schedule, Acquisition Update, and Executive Appointment - Analyst Notes on Allergan, Pfizer, Eli Lilly, Forest and Pharmacyclics
PR Newswire - Tue May 27, 6:20AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan, Inc. (NYSE: AGN), Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), Forest Laboratories, Inc. (NYSE: FRX) and Pharmacyclics, Inc. (NASDAQ: PCYC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2970-100free.
Research and Markets: Global Antibacterial Drugs Market Research Report 2014: Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides and Phenicols
Business Wire - Tue May 27, 3:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pdgs5q/antibacterial) has announced the addition of the "Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering.
Global Antibacterial Drugs Market Research Report 2014: Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides and Phenicols
M2 - Tue May 27, 2:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vjlj88/antibacterial) has announced the addition of the "Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Sanofi are the major players engaged in the development, production and marketing of various antibacterial drugs. The global antibacterial drugs market has been categorized into seven segments based on their class, namely, aminoglycosides, ?-lactams, tetracyclines, sulfonamides, quinolones/ fluoroquinolones, macrolides and phenicols. In 2012, ?-lactams class occupied the leading position with a share of 57.1% of the global antibacterial drugs market followed by the quinolones. However, these drug classes are expected to witness decline in their market share during the forecast period due to patent expiry of key branded formulations and growing number of drug resistant bacterial strains. Hence, on account of the above mentioned factors, the global antibacterial drugs market is expected to witness slow growth during the forecast period 2013 to 2019. However, growing demand for therapies against bacterial infections and rising elderly populations are some of the factors that are anticipated to maintain steady growth of the antibacterial drugs market. Additionally, expected launch of various antibacterial agents that are currently in developmental stages, such as tedizolid (Cubist Pharmaceuticals), Dalvance (Durata Therapeutics), surotomycin (Cubist Pharmaceuticals), MK-3415A (Merck) during the forecast period is also expected to restore growth of this market. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Antibacterial Drugs Market Revenue, by Class, 2011 - 2019 (USD Million) Chapter 5 Global Antibacterial Drugs Market Revenue, Pipeline Analysis (USD Million) Chapter 6 Global Antibacterial Drugs Market Revenue, by Geography, 2011 - 2019 (USD Million) Chapter 7 Competitive Landscape Chapter 8 Recommendations Chapter 9 Company Profiles - AstraZeneca plc - Bayer AG - Bristol-Myers Squibb Company - Eli Lilly and Company - Forest Laboratories, Inc. - GlaxoSmithKline plc - Johnson & Johnson - Merck & Co., Inc. - Novartis AG - Pfizer, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/vj...ibacterial
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of Furiex Pharmaceuticals, Inc. of Claims Against Board of Directors of Company in Connection With the Sale of the Company to Forest Laboratories, Inc. -- FURX
GlobeNewswire - Fri May 23, 1:01PM CDT
Levi & Korsinsky reminds investors of Furiex Pharmaceuticals, Inc. ("Furiex" or "the Company"
(Nasdaq:FURX) of claims of breaches of fiduciary duty and other violations of state law against the board of directors of the Company in connection with the sale of the Company to Forest Laboratories, Inc. ("Forest" . A complaint was filed in Delaware state court. Milestone Payments for Adamas - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 22, 4:10PM CDT
Adamas (ADMS) received a milestone payment of $25 million from Forest Labs (FRX) related to MDX-8704.
SHAREHOLDER ALERT: Brower Piven Announces Class Action Lawsuit in Connection with the Sale of Furiex Pharmaceuticals, Inc. to Forest Laboratories, Inc. and Royal Empress, Inc.
Business Wire - Thu May 22, 2:39PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the Delaware Chancery Court on behalf of all common stockholders of Furiex Pharmaceuticals, Inc. ("Furiex" or the "Company"
(NasdaqGS: FURX) asserting claims that the members of the Company's board of directors have breached fiduciary duties they owe to Furiex shareholders. Research and Markets: Global Neuropathic Pain Report 2014: Grnenthal's Cebranopadol - Forecast and Market Analysis to 2022
Business Wire - Thu May 22, 11:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q53s8z/cebranopadol) has announced the addition of the "Cebranopadol (Neuropathic Pain) - Forecast and Market Analysis to 2022" report to their offering.
Global Neuropathic Pain Report 2014: Grunenthal's Cebranopadol - Forecast and Market Analysis to 2022
M2 - Thu May 22, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8s2vl4/cebranopadol) has announced the addition of the "Cebranopadol (Neuropathic Pain) - Forecast and Market Analysis to 2022" report to their offering. Cebranopadol (GRT-6005) is a small-molecule opioid analgesic that is being developed by Gr?nenthal for the treatment of moderate to severe chronic pain conditions. In December 2010, Gr?nenthal entered into a licensing agreement with Forest Laboratories for the co-development and commercialization of cebranopadol and its follow-on compound, GRT-6006. The drug is currently in Phase IIb of clinical development for PDN, and is also in Phase III of development for cancer pain, as well as in Phase II for chronic nociceptive pain, moderate to severe pain due to osteoarthritis of the knee, and chronic low back pain. Scope - Overview of Neuropathic pain, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Cebranopadol including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Cebranopadol for the top six countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain and the UK. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview - Painful Diabetic Neuropathy - Postherpetic Neuralgia - Trigeminal Neuralgia - Etiology - Pathophysiology 4 Disease Management - Diagnosis - Treatment Overview and Guidelines 5 Competitive Assessment 6 Unmet Need and Opportunity - Physician Knowledge or Awareness - Diagnostic Challenges - Low Treatment Rate and Underdosing of Medications - Unsatisfactory Efficacy and Safety Profiles of Pharmacological Treatments - Elderly Patient Population - Drug Tolerability - Rational or Personalized Therapies 7 Pipeline Assessment - Promising Drugs in Clinical Development 8 Cebranopadol - Overview - Efficacy - Safety - Dosing and Formulation - Potential Clinical and Commercial Positioning - Pricing and Reimbursement - SWOT Analysis - Forecast 9 Appendix For more information visit http://www.researchandmarkets.com/research/8s...branopadol
